Authors

Jyoti D. Patel, MD Northwestern&nbsp

Jyoti D. Patel, MD NorthwesternÂ

Jyoti D. Patel, MD, Robert H. Lurie Comprehensive Cancer Center

Latest:

TRK Inhibitors in Lung and GI Cancers

Jyoti D. Patel, MD, University of Chicago

Jyoti Malhotra, MD, MPH

Jyoti Malhotra, MD, MPH, is the interim division chief of Thoracic Medical Oncology at City of Hope, and an associate professor in the Department of Medical Oncology & Therapeutics and research director of Thoracic Medical Oncology at City of Hope Orange County.

Latest:

Ongoing Sigvotatug Vedotin Exploration Highlights Potential for Biomarker Advancement in NSCLC: With Edward S. Kim, MD, MBA; and Jyoti Malhotra, MD, MPH

Drs Kim and Malhotra discuss factors that make IB6 unique vs other NSCLC biomarkers and the study of sigvotatug vedotin in previously treated NSCLC.

Jyoti Patel, MD

Latest:

Dr Patel on Findings From the TRUST-II Trial in ROS1+ NSCLC

Jyoti Patel, MD, discusses the implications of the TRUST-II trial in locally advanced or metastatic ROS1-positive NSCLC, regardless of prior TKI exposure.

K. Michael Cummings, PhD, MPH

Latest:

Helping Cancer Patients Quit Smoking Should Be a Standard of Care

Most oncologists do not regularly provide evidence-based tobacco cessation support for patients with cancer who smoke. However, addressing tobacco use is not as difficult as some might think.

Kabir Mody, MD

Latest:

Dr. Mody on Progress Made With Y-90 in Hepatocellular Carcinoma

Kabir Mody, MD discusses new directions with yttrium-90 glass microspheres in hepatocellular carcinoma as demonstrated in the retrospective LEGACY study.

Kabir Mody, MD, Mayo Clinic Cancer Center

Kaleb H. Yohay, MD, NYU Langone Health

Latest:

Management of Neurofibromatosis Type 1 with Plexiform Neurofibromas (NF1 with PNs)

Kami Maddocks, MD, The Ohio State University

Latest:

Evolving Therapies in R/R DLBCL: Concluding Remarks

Kandace McGuire, MD

Latest:

Leveraging Genomic Assays to Guide Treatment Decisions: Clinical Scenarios and Expert Perspectives

Panelists discuss how genomic testing informs real clinical scenarios, demonstrating that for a 64-year-old healthy woman with a single positive lymph node, the 21-gene assay would guide treatment decisions, with cardiac assessment influencing whether anthracycline-based chemotherapy would be used if her score was high.

Kanti R. Rai, MD

Latest:

CLL in the Era of Targeted Therapies

Over the past few years, remarkable advances have been achieved in the field of chronic lymphocytic leukemia by rationally targeting pathways overexpressed and used by the malignant clone for proliferation and survival.

Kanwal Raghav, MBBS, MD

Kanwal P.S. Raghav, MBBS, MD, is an associate professor in the Department of Gastrointestinal Medical Oncology; associate vice president in the Department of Ambulatory Medical Operations, Division of Cancer Medicine; and executive medical director of the Department of Ambulatory Treatment Centers at The University of Texas MD Anderson Cancer Center in Houston.

Latest:

Sequencing, Efficacy, and Safety Data May Further Evolve the Role of Fruquintinib in CRC: With Kanwal P. S. Raghav, MBBS, MD

Dr Raghav discusses the role of fruquintinib in the treatment of adult patients with pretreated, metastatic colorectal cancer.

Kanwal Raghav, MD

Latest:

Metastatic Colorectal Cancer: Future Directions in Care

Expert panelists identify key takeaways and share their excitement for future directions in the management of metastatic colorectal cancer.

Kapil N. Bhalla, MD

Latest:

Dr. Bhalla on Sensitizing TNBC to PARP Inhibitors and Cisplatin

Kapil N. Bhalla, MD, from the University of Kansas Cancer Center, describes an in vivo study that examined treatment with histone deacetylase inhibitors in triple-negative breast cancer cells.

Kapodistrian University of Athens School of Medicine

Kara D. Forinash, MS, PA-C, Shari Pilon-Thomas, PhD

Latest:

Immunotherapy Combined With Chemotherapy for Pancreatic Cancer: A Game Changer?

This article reviews up-to-date clinical studies combining chemotherapy with immunotherapy; it also explains the rationale for this combination in treatment of pancreatic cancer.

Kareem Abdul-Jabbar

Latest:

Kareem Abdul-Jabbar Discusses Living With CML

Kareem Abdul-Jabbar, retired NBA player for the Milwaukee Bucks and the Los Angeles Lakers, discusses his experience with chronic myeloid leukemiaâ€Ž (CML) at the 20th Annual International Congress on Hematologic Malignancies: Focus on Leukemias, Lymphomas and Myeloma, held March 18.

Karen E. Hoffman, MD

Latest:

Dr. Hoffman on the Urologist's Influence on Treatment Choice

Karen E. Hoffman, MD, MHSc, MPH, from the MD Anderson Cancer Center, describes the diagnosing urologist's influence on the initial treatment selected for elderly men with favorable prostate cancer.